What to consider when conducting a cost-effectiveness analysis in a clinical setting

被引:7
|
作者
Naglak, M
Mitchell, DC
Kris-Etherton, P
Harkness, W
Pearson, TA
机构
[1] W Chester Univ, Dept Hlth, W Chester, PA 19380 USA
[2] Penn State Univ, Dept Nutr, University Pk, PA 16802 USA
[3] Penn State Univ, Diet Assessment Serv, University Pk, PA 16802 USA
[4] Penn State Univ, Dept Nutr, University Pk, PA 16802 USA
[5] Penn State Univ, Dept Stat, University Pk, PA 16802 USA
[6] Univ Rochester, Dept Community & Prevent Med, Rochester, NY USA
[7] Mary Imogene Bassett Res Inst, Cooperstown, NY USA
[8] Columbia Univ, Cooperstown, NY USA
关键词
D O I
10.1016/S0002-8223(98)00266-1
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
More data are needed providing strong evidence that nutrition services are cost-effective. Economic evaluations, such as cost-effectiveness analyses, are excellent practice-based research projects. We conducted a cost-effectiveness analysis in a clinical setting to compare the cost-effectiveness of lipid-lowering medications plus diet therapy (medication+diet) with diet therapy alone (diet alone) for treating patients with hypercholesterolemia. Twenty-five adults with hypercholesterolemia (13 receiving medication+diet, 12 receiving diet alone) either participated in an 8-week, home-based, step 1 intervention or were counseled about diet and lifestyle by their care provider. Diet, cost, and laboratory data were collected at baseline, at 9 months, and at 19 months after participation in the intervention (follow-up). Cost per unit change in outcome was evaluated for each group. The diet-alone group made only small changes in dietary Intake, changes that were smaller in magnitude than those made by the medication+diet group. Nevertheless, at 9 months, costs per unit change in total serum cholesterol level and low-density lipoprotein cholesterol (LDL-C) level were approximately $24 and $83 less, respectively, for the diet-alone group. At follow-up, however, the cost per unit change in LDL-C level was approximately $17 less for the medication+diet group, which can be explained by the medication+diet group's greater decrease in LDL-C level. The following elements should be considered when conducting a cost-effectiveness analysis of medical nutrition therapy: effectiveness of the nutrition intervention, adequate sample size, confounding variables, compliance with diet and drug therapy, direct and indirect costs of care, and follow-up evaluation.
引用
收藏
页码:1149 / 1154
页数:6
相关论文
共 50 条
  • [1] What is the Role of Cost-Effectiveness Analysis in Clinical Practice?
    Erickson, Bradley A.
    JOURNAL OF UROLOGY, 2013, 190 (04): : 1163 - 1164
  • [2] WHAT IS COST-EFFECTIVENESS ANALYSIS
    EVANS, DB
    MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 : S7 - S9
  • [3] What is a cost-effectiveness analysis?
    Harper, DM
    ARCHIVES OF FAMILY MEDICINE, 1997, 6 (06) : 527 - 528
  • [4] Cost-effectiveness analysis has to consider all available evidence when informing inputs
    Alvarez, Fabian P.
    Petitjean, Audrey
    Nealon, Joshua
    Hollingsworth, Rosalind
    Lopez-Belmonte, Juan Luis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 694 - 695
  • [5] Cost-effectiveness analysis for priority-setting in South Africa - what are the possibilities?
    Doherty, Jane
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2010, 100 (12): : 816 - 821
  • [6] What is a cost-effectiveness analysis? Reply
    Chesebro, MJ
    ARCHIVES OF FAMILY MEDICINE, 1997, 6 (06) : 528 - 528
  • [7] Conducting a Cost-Effectiveness Analysis of an Early Numeracy Intervention
    Clarke, Ben
    Cil, Gulcan
    Smolkowski, Keith
    Sutherland, Marah
    Turtura, Jessica
    Doabler, Christian T.
    Fien, Hank
    Baker, Scott K.
    SCHOOL PSYCHOLOGY REVIEW, 2020, 49 (04) : 359 - 373
  • [8] MARROW TRANSPLANTATION, COST-EFFECTIVENESS ANALYSIS AND SETTING LIMITS
    WELCH, HG
    LEUKEMIA, 1993, 7 (07) : 1108 - 1111
  • [9] Cost-effectiveness analysis in a setting of budget constraints - Is it equitable?
    Ubel, PA
    DeKay, ML
    Baron, J
    Asch, DA
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (18): : 1174 - 1177
  • [10] Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting
    Finley, PR
    Sommer, B
    Corbitt, JL
    Brunson, GH
    Lum, BG
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 524 - 524